Moscow Develops 11 New Biomolecules for Cancer and Autoimmune Diseases
Moscow-based R-Farm is developing 11 original biomolecules for treating cancer and autoimmune diseases, using advanced biotechnologies such as monoclonal antibodies, ADCs, and RNA/gene therapy, with support from the city government.
Consensus
- R-Farm is developing 11 original biomolecules for treating cancer and autoimmune diseases.
- The development is taking place at the Center for Biotechnological Process Development at the 'Sputnik Technopolis' factory.
- The center is a resident of the 'Technopolis Moscow' special economic zone.
- The projects are part of a broader portfolio of 22 initiatives by R-Farm focused on original molecules and biosimilars.
- The technologies used include monoclonal and multispecific antibodies, antibody-drug conjugates (ADC), RNA therapy, and gene therapy.
- The research aims to treat oncological, autoimmune, and neurodegenerative diseases.
- The city of Moscow supports the development of the pharmaceutical industry and helps companies adopt new technologies and expand production.
- There is growing focus on therapies for maintaining health and active longevity, including treatments for neurodegenerative diseases and age-related changes.
Points of divergence
- The center has been conducting research on its own scientific base since 2023. — mn
- The center has been operating since 2023. — m24
- R-Farm is working on drugs for neurodegenerative diseases and longevity-enhancing agents. — mn
- R-Farm has announced a program for patient access to the drug 'Camrelizumab' for triple-negative breast cancer before full state funding. — m24
Coverage (2 sources)
- In Moscow, 11 new molecules are being developed for the treatment of cancer and autoimmune diseases — Московские новости
- In Moscow, 11 biomolecules will be developed for therapy of oncological and autoimmune diseases — Москва 24